PF 337210
Alternative Names: PF-00337210; PF-337210Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antineoplastics; Benzofurans; Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (PO, Capsule)
- 08 Jun 2010 Adverse events, pharmacokinetics, pharmacodynamics and efficacy data from a phase I trial in late-stage Solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
- 11 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics and pharmacokinetics sections